Government-Owned Inventions; Availability for Licensing, 67740-67741 [E7-23194]
Download as PDF
<![CDATA[
67740
Federal Register / Vol. 72, No. 230 / Friday, November 30, 2007 / Notices
and for identification of agents which
cause or reverse immunosuppression.
Development Status: Pre-clinical
stage.
Inventors: Augusto C. Ochoa et al.
(NCI).
Patent Status: U.S. Patent No.
5,583,002 issued 10 Dec 1996 (HHS
Reference No. E–231–1995/1–US–01);
U.S. Patent No. 5,556,763 issued 17
Sep 1996 (HHS Reference No. E–231–
1995/3–US–01);
U.S. Patent No. 5,889,143 issued 10
Dec 1996 (HHS Reference No. E–231–
1995/3–US–02);
U.S. Patent Application No. 09/
280,655 filed 29 Mar 1999 (HHS
Reference No. E–231–1995/3–US–03);
U.S. Patent No. 5,658,744 issued 19
Aug 1997 (HHS Reference No. E–232–
1995/0–US–01);
U.S. Patent No. 5,965,366 issued 12
Dec 1999 (HHS Reference No. E–232–
1995/1–US–01); and any foreign
equivalent patents and patent
applications.
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: John Stansberry;
301/435–5236; stansbej@mail.nih.gov.
Dated: November 14, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–23193 Filed 11–29–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
rwilkins on PROD1PC63 with NOTICES
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the United States in
accordance with 35 U.S.C. 207 to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
VerDate Aug<31>2005
16:27 Nov 29, 2007
Jkt 214001
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Monoclonal Antibody to a Specific
Peptide–MHC Class II Complex
Description of Invention: T
lymphocytes play an important role in
the immune system by recognizing
foreign protein motifs on cells. T
lymphocytes are stimulated to recognize
these motifs through their interactions
with peptide-MHC complexes (pMHC).
Thus, studying pMHC is an important
aspect of understanding how the
immune system works, particularly with
regard to the development of vaccines.
Unfortunately, the detection of pMHC is
largely dependent on indirect assays,
due to the difficulty of producing
antibodies for specific pMHC.
This invention regards the
development of hybridomas (C4H3) for
the production of antibodies that are
highly specific for a particular pMHC
complex consisting of hen egg lysozyme
peptide 46-61 (HEL) and the I-Ak MHC
class II molecule. These antibodies can
be used for a myriad of purposes which
include studying how cells form pMHC.
Applications: Discovery of methods
for antigen delivery in the development
of vaccines.
Quantitation and distribution of
pMHC complexes on cells.
Study antigen processing in
experimental immunological research
systems.
Advantages: High specificity for the
pMHC complex of HEL-I-Ak MHC class
II molecule.
HEL-I-Ak is widely used in
experimental immunological research
systems, giving the hybridoma and
antibodies great applicability.
Inventors: Ronald N. Germain et al.
(NIAID).
Publications: 1. G Zhong et al.
Production, specificity, and
functionality of monoclonal antibodies
to specific peptide-major
histocompatibility complex class II
complexes formed by processing of
exogenous protein. Proc Natl Acad Sci
U S A. 1997 Dec 9; 94(25):13856–13861.
2. A Porgador et al. Localization,
quantitation, and in situ detection of
specific peptide-MHC class I complexes
using a monoclonal antibody.
Immunity. 1997 Jun; 6(6):715–726.
Patent Status: HHS Reference No. E–
021–2008/0–Research Tool. Patent
protection is not being pursued for this
technology.
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
Licensing Contact: David A.
Lambertson, Ph.D.; 301–435–4632;
lambertsond@mail.nih.gov.
Collaborative Research Opportunity:
The NIAID Lymphocyte Biology
Section, Laboratory of Immunology is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize
monoclonal antibody C4H3, specific for
HEL (46-61) bound to the MHC class II
molecule I-Ak. Please contact Ronald N.
Germain, M.D., Ph.D., at
rgermain@nih.gov for more information.
Bifunctional Compounds that Bind to
Hormone Receptors
Description of Technology: The
development and progression of
prostate cancer is dependent on the
androgen receptor (AR), a liganddependent transcription factor. In the
inactive form AR resides in the cytosolic
region of the cell and when activated,
AR is imported into the nucleus. Initial
hormonal therapy for prostate cancer
involves lowering serum levels of
testosterone to shut down AR activity.
Despite initial patient responses to
testosterone-depleting therapies,
prostate cancer becomes refractory to
hormonal therapy. Notably, AR is
reactivated in hormone-refractory
prostate cancer and reinstates its
proliferative and survival activity.
Available for licensing is a novel
chemical compound which is
bifunctional and binds to AR. This
compound is comprised of tubulinbinding and steroid receptor-binding
moieties. This compound is designed to
antagonize AR function in a
nonclassical manner by several
mechanisms and kills hormonerefractory prostate cells better than both
functional moieties. This compound is a
first-in-class of bifunctional steroid
receptor binding agents that can
antagonize steroid receptors in a variety
of hormone-dependent diseases, such as
breast and prostate cancer.
Applications: Therapeutic
compounds that selectively target
steroid receptor-expressing cancer cells
resulting in decreased toxicity.
Method to treat hormone resistant
prostate cancer and potentially other
steroid receptor dependent diseases
such as breast cancer.
Market: Prostate cancer is the second
most common type of cancer among
men, wherein one in six men will be
diagnosed with prostate cancer.
An estimated 218,890 new cases of
prostate cancer and 27,050 deaths due
to prostate cancer in the United States
in 2007.
E:\FR\FM\30NON1.SGM
30NON1
Federal Register / Vol. 72, No. 230 / Friday, November 30, 2007 / Notices
rwilkins on PROD1PC63 with NOTICES
An estimated 180,510 new cases of
breast cancer and 40,060 deaths due to
breast cancer in the United States in
2007.
Development Status: The technology
is currently in the pre-clinical stage of
development.
Inventors: Nima Sharifi et al. (NCI).
Patent Status: U.S. Provisional
Application No. 60/958,351 filed 03 Jul
2007 (HHS Reference No. E–163–2007/
0–US–01).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Jennifer Wong;
301–435–4633; wongje@mail.nih.gov.
Collaborative Research Opportunity:
The Medical Oncology Branch, National
Cancer Institute is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize—treatments of resistant
prostate cancer. Please contact John D.
Hewes, Ph.D. at 301–435–3121 or
hewesj@mail.nih.gov for more
information.
A Clinically Proven Therapeutic
Treatment and Diagnostic Tool for
Mesothelin Expressing Cancers: A
Novel Recombinant Immunotoxin SS1P
(anti-mesothelin dsFv–PE38)
Description of Technology:
Mesothelin is a glycoprotein, whose
expression has been largely restricted to
mesothelial cells in normal tissues.
Mesothelin has been shown to be
expressed in several cancers including
mesothelioma, lung cancer, pancreatic
cancers, gastric cancers and ovarian
cancers, and has the potential of being
used as a novel target for the
development of new treatments.
The technology relates to the SSIP
immunotoxin that can be used to kill
cells expressing mesothelin on their
surfaces, such as mesothelioma, ovarian
cancer, lung cancer, ovarian cancer and
stomach cancer. Additionally, it can be
used for the detection of mesothelin
expressing cells present in a biological
sample.
The SSIP immunotoxin is a
recombinant immunotoxin generated by
the fusion of a high affinity antimesothelin Fv (SS1) with a 38 kDa
portion of Pseudomonas Exotoxin A
(PE38).
Applications: SS1P can be used as a
therapy for mesothelin expressing
cancers.
The immunotoxin can be used as a
stand alone treatment and in
combination with standard
chemotherapy.
Advantage: SS1P immunotoxin is
available for use and has been
successfully tested clinically for the
VerDate Aug<31>2005
16:27 Nov 29, 2007
Jkt 214001
treatment of mesothelioma and ovarian
cancer with low side effects.
Development Status: Phase 1 studies
have been completed for mesothelin
expressing cancers such as
mesothelioma, ovarian cancer and
pancreatic cancer.
Phase 2 studies to begin shortly for
combination therapy using SS1P and
standard chemotherapy.
Inventors: Ira Pastan (NCI) et al.
Relevant Publications: 1. R Hassan et
al. Phase I study of SS1P, a recombinant
anti-mesothelin immunotoxin given as a
bolus I.V. infusion to patients with
mesothelin-expressing mesothelioma,
ovarian, and pancreatic cancers. Clin
Cancer Res. 2007 Sep 1;13 (17):5144–
5149.
2. Y Zhang et al. Synergistic
antitumor activity of taxol and
immunotoxin SS1P in tumor-bearing
mice. Clin Cancer Res. 2006 Aug
1;12(15):4695–4701.
Patent Status: U.S. Patent No.
7,081,518 issued 25 Jul 2006, entitled
‘‘Anti-Mesothelin Antibodies Having
High Binding Affinity’’ (HHS Reference
No. E–139–1999/0–US–07)
Related Intellectual Property: 1. U.S.
Patent No. 4,892,827 entitled
‘‘Recombinant Pseudomonas Exotoxin:
Construction of an Active Immunotoxin
with Low Side Effects’’ [HHS Ref. No.
E–385–1986/0];
2. U.S. Patent Nos. 6,051,405,
5,863,745, and 5,696,237 ‘‘Recombinant
Antibody-Toxin Fusion Protein’’ [HHS
Ref. No. E–135–1989/0];
3. U.S. Patents 5,747,654, 6,147,203,
and 6,558,672 entitled ‘‘Recombinant
Disulfide-Stabilized Polypeptide
Fragments Having Binding Specificity’’
[HHS Ref. No. E–163–1993/0];
4. U.S. Patent No. 6,153,430, and U.S.
Patent Application No. 09/684,599
‘‘Nucleic Acid Encoding Mesothelin, a
Differentiation Antigen Present on
Mesothelium, Mesotheliomas and
Ovarian Cancers’’ [HHS Ref. No. E–002–
1996/0];
5. U.S. Patent 6,083,502 entitled
‘‘Mesothelium Antigen and Methods
and Kits for Targeting It’’ [HHS Ref. No.
E–002–1996/1];
6. U.S. Patent Application 09/581,345:
‘‘Antibodies, Including Fv Molecules,
and Immunoconjugates Having High
Binding Affinity for Mesothelin and
Methods for Their Use’’ [HHS Ref. No.
E–021–1998/0];
7. PCT Application No. PCT/US01/
18503, ‘‘Pegylation of Linkers Improves
Antitumor Activity and Reduces
Toxicity of Immunoconjugates’’ [HHS
Ref. No. E–216–2000/2];
8. PCT Application No. PCT/US2006/
018502 and U.S. Patent Application No.
60/681,104, entitled ‘‘Anti-Mesothelin
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
67741
Antibodies Useful For Immunological
Assays’’ [HHS Ref. No. E–015–2005/0–
US–01]; and
9. Any related foreign filed national
stage applications claiming priority to
such patent applications and patents
listed above.
Licensing Status: Available for
exclusive and non-exclusive licensing.
Licensing Contact: David A.
Lambertson, Ph.D.; 301–435–4632;
lambertsond@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute
Laboratory of Molecular Biology is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, immunotoxin SS1P. Please
contact John D. Hewes, Ph.D. at 301–
435–3121 or hewesj@mail.nih.gov for
more information.
Dated: November 16, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–23194 Filed 11–29–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Human Genome Research
Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Inherited
Disease Research Access Committee.
Date: January 10–11, 2008.
Time: 7 a.m. to 3:45 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road, NW.,
Washington, DC 20015.
Contact Person: Jerry Roberts, PhD.,
Scientific Review Officer, Scientific Review
Branch, National Human Genome Research
Institute, National Institutes of Health, 5635
E:\FR\FM\30NON1.SGM
30NON1
]]>Agencies
[Federal Register Volume 72, Number 230 (Friday, November 30, 2007)]
[Notices]
[Pages 67740-67741]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-23194]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the United States in
accordance with 35 U.S.C. 207 to achieve expeditious commercialization
of results of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Monoclonal Antibody to a Specific Peptide-MHC Class II Complex
Description of Invention: T lymphocytes play an important role in
the immune system by recognizing foreign protein motifs on cells. T
lymphocytes are stimulated to recognize these motifs through their
interactions with peptide-MHC complexes (pMHC). Thus, studying pMHC is
an important aspect of understanding how the immune system works,
particularly with regard to the development of vaccines. Unfortunately,
the detection of pMHC is largely dependent on indirect assays, due to
the difficulty of producing antibodies for specific pMHC.
This invention regards the development of hybridomas (C4H3) for the
production of antibodies that are highly specific for a particular pMHC
complex consisting of hen egg lysozyme peptide 46-61 (HEL) and the I-
A\k\ MHC class II molecule. These antibodies can be used for a myriad
of purposes which include studying how cells form pMHC.
Applications: Discovery of methods for antigen delivery in the
development of vaccines.
Quantitation and distribution of pMHC complexes on cells.
Study antigen processing in experimental immunological research
systems.
Advantages: High specificity for the pMHC complex of HEL-I-A\k\ MHC
class II molecule.
HEL-I-A\k\ is widely used in experimental immunological research
systems, giving the hybridoma and antibodies great applicability.
Inventors: Ronald N. Germain et al. (NIAID).
Publications: 1. G Zhong et al. Production, specificity, and
functionality of monoclonal antibodies to specific peptide-major
histocompatibility complex class II complexes formed by processing of
exogenous protein. Proc Natl Acad Sci U S A. 1997 Dec 9; 94(25):13856-
13861.
2. A Porgador et al. Localization, quantitation, and in situ
detection of specific peptide-MHC class I complexes using a monoclonal
antibody. Immunity. 1997 Jun; 6(6):715-726.
Patent Status: HHS Reference No. E-021-2008/0-Research Tool. Patent
protection is not being pursued for this technology.
Licensing Contact: David A. Lambertson, Ph.D.; 301-435-4632;
lambertsond@mail.nih.gov.
Collaborative Research Opportunity: The NIAID Lymphocyte Biology
Section, Laboratory of Immunology is seeking statements of capability
or interest from parties interested in collaborative research to
further develop, evaluate, or commercialize monoclonal antibody C4H3,
specific for HEL (46-61) bound to the MHC class II molecule I-A\k\.
Please contact Ronald N. Germain, M.D., Ph.D., at rgermain@nih.gov for
more information.
Bifunctional Compounds that Bind to Hormone Receptors
Description of Technology: The development and progression of
prostate cancer is dependent on the androgen receptor (AR), a ligand-
dependent transcription factor. In the inactive form AR resides in the
cytosolic region of the cell and when activated, AR is imported into
the nucleus. Initial hormonal therapy for prostate cancer involves
lowering serum levels of testosterone to shut down AR activity. Despite
initial patient responses to testosterone-depleting therapies, prostate
cancer becomes refractory to hormonal therapy. Notably, AR is
reactivated in hormone-refractory prostate cancer and reinstates its
proliferative and survival activity.
Available for licensing is a novel chemical compound which is
bifunctional and binds to AR. This compound is comprised of tubulin-
binding and steroid receptor-binding moieties. This compound is
designed to antagonize AR function in a nonclassical manner by several
mechanisms and kills hormone-refractory prostate cells better than both
functional moieties. This compound is a first-in-class of bifunctional
steroid receptor binding agents that can antagonize steroid receptors
in a variety of hormone-dependent diseases, such as breast and prostate
cancer.
Applications: Therapeutic compounds that selectively target steroid
receptor-expressing cancer cells resulting in decreased toxicity.
Method to treat hormone resistant prostate cancer and potentially
other steroid receptor dependent diseases such as breast cancer.
Market: Prostate cancer is the second most common type of cancer
among men, wherein one in six men will be diagnosed with prostate
cancer.
An estimated 218,890 new cases of prostate cancer and 27,050 deaths
due to prostate cancer in the United States in 2007.
[[Page 67741]]
An estimated 180,510 new cases of breast cancer and 40,060 deaths
due to breast cancer in the United States in 2007.
Development Status: The technology is currently in the pre-clinical
stage of development.
Inventors: Nima Sharifi et al. (NCI).
Patent Status: U.S. Provisional Application No. 60/958,351 filed 03
Jul 2007 (HHS Reference No. E-163-2007/0-US-01).
Licensing Status: Available for exclusive or non-exclusive
licensing.
Licensing Contact: Jennifer Wong; 301-435-4633;
wongje@mail.nih.gov.
Collaborative Research Opportunity: The Medical Oncology Branch,
National Cancer Institute is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize--treatments of resistant prostate
cancer. Please contact John D. Hewes, Ph.D. at 301-435-3121 or
hewesj@mail.nih.gov for more information.
A Clinically Proven Therapeutic Treatment and Diagnostic Tool for
Mesothelin Expressing Cancers: A Novel Recombinant Immunotoxin SS1P
(anti-mesothelin dsFv-PE38)
Description of Technology: Mesothelin is a glycoprotein, whose
expression has been largely restricted to mesothelial cells in normal
tissues. Mesothelin has been shown to be expressed in several cancers
including mesothelioma, lung cancer, pancreatic cancers, gastric
cancers and ovarian cancers, and has the potential of being used as a
novel target for the development of new treatments.
The technology relates to the SSIP immunotoxin that can be used to
kill cells expressing mesothelin on their surfaces, such as
mesothelioma, ovarian cancer, lung cancer, ovarian cancer and stomach
cancer. Additionally, it can be used for the detection of mesothelin
expressing cells present in a biological sample.
The SSIP immunotoxin is a recombinant immunotoxin generated by the
fusion of a high affinity anti-mesothelin Fv (SS1) with a 38 kDa
portion of Pseudomonas Exotoxin A (PE38).
Applications: SS1P can be used as a therapy for mesothelin
expressing cancers.
The immunotoxin can be used as a stand alone treatment and in
combination with standard chemotherapy.
Advantage: SS1P immunotoxin is available for use and has been
successfully tested clinically for the treatment of mesothelioma and
ovarian cancer with low side effects.
Development Status: Phase 1 studies have been completed for
mesothelin expressing cancers such as mesothelioma, ovarian cancer and
pancreatic cancer.
Phase 2 studies to begin shortly for combination therapy using SS1P
and standard chemotherapy.
Inventors: Ira Pastan (NCI) et al.
Relevant Publications: 1. R Hassan et al. Phase I study of SS1P, a
recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion
to patients with mesothelin-expressing mesothelioma, ovarian, and
pancreatic cancers. Clin Cancer Res. 2007 Sep 1;13 (17):5144-5149.
2. Y Zhang et al. Synergistic antitumor activity of taxol and
immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res. 2006 Aug
1;12(15):4695-4701.
Patent Status: U.S. Patent No. 7,081,518 issued 25 Jul 2006,
entitled ``Anti-Mesothelin Antibodies Having High Binding Affinity''
(HHS Reference No. E-139-1999/0-US-07)
Related Intellectual Property: 1. U.S. Patent No. 4,892,827
entitled ``Recombinant Pseudomonas Exotoxin: Construction of an Active
Immunotoxin with Low Side Effects'' [HHS Ref. No. E-385-1986/0];
2. U.S. Patent Nos. 6,051,405, 5,863,745, and 5,696,237
``Recombinant Antibody-Toxin Fusion Protein'' [HHS Ref. No. E-135-1989/
0];
3. U.S. Patents 5,747,654, 6,147,203, and 6,558,672 entitled
``Recombinant Disulfide-Stabilized Polypeptide Fragments Having Binding
Specificity'' [HHS Ref. No. E-163-1993/0];
4. U.S. Patent No. 6,153,430, and U.S. Patent Application No. 09/
684,599 ``Nucleic Acid Encoding Mesothelin, a Differentiation Antigen
Present on Mesothelium, Mesotheliomas and Ovarian Cancers'' [HHS Ref.
No. E-002-1996/0];
5. U.S. Patent 6,083,502 entitled ``Mesothelium Antigen and Methods
and Kits for Targeting It'' [HHS Ref. No. E-002-1996/1];
6. U.S. Patent Application 09/581,345: ``Antibodies, Including Fv
Molecules, and Immunoconjugates Having High Binding Affinity for
Mesothelin and Methods for Their Use'' [HHS Ref. No. E-021-1998/0];
7. PCT Application No. PCT/US01/18503, ``Pegylation of Linkers
Improves Antitumor Activity and Reduces Toxicity of Immunoconjugates''
[HHS Ref. No. E-216-2000/2];
8. PCT Application No. PCT/US2006/018502 and U.S. Patent
Application No. 60/681,104, entitled ``Anti-Mesothelin Antibodies
Useful For Immunological Assays'' [HHS Ref. No. E-015-2005/0-US-01];
and
9. Any related foreign filed national stage applications claiming
priority to such patent applications and patents listed above.
Licensing Status: Available for exclusive and non-exclusive
licensing.
Licensing Contact: David A. Lambertson, Ph.D.; 301-435-4632;
lambertsond@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute
Laboratory of Molecular Biology is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, immunotoxin SS1P. Please contact John D. Hewes, Ph.D. at 301-
435-3121 or hewesj@mail.nih.gov for more information.
Dated: November 16, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E7-23194 Filed 11-29-07; 8:45 am]
BILLING CODE 4140-01-P
